Ptaszyński Konrad, Szumera-Ciećkiewicz Anna, Zakrzewska Klara, Tuziak Tomasz, Mrozkowiak Anna, Rutkowski Piotr
Department of Pathology, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw.
Pol J Pathol. 2009;60(1):10-8.
Synovial sarcoma (SyS) occurs mostly in young adults and is characterized by an aggressive course. Combined treatment including chemotherapy, radiotherapy and surgical excision of the tumour is still not satisfactory, with mean 5-year survival of 30-50%. New targeted treatment options have appeared recently, e.g. HER2 and EGFR antagonists. Initial studies have revealed immunohistochemical overexpression of the EGFR in SyS; therefore trials with EGFR antagonist therapy have commenced. The aim of our study was to evaluate the status of HER2, EGFR and TOPIIA in SyS before and after combined therapy. Immunohistochemistry and FISH tests were performed. Significant discrepancies between protein expression and gene status were found. The authors discuss the potential reasons for that phenomenon.
滑膜肉瘤（SyS）多发生于年轻人，病程呈侵袭性。包括化疗、放疗及肿瘤手术切除在内的联合治疗效果仍不尽人意，平均5年生存率为30%-50%。近期出现了新的靶向治疗方案，如HER2和EGFR拮抗剂。初步研究显示EGFR在滑膜肉瘤中存在免疫组化过表达；因此，EGFR拮抗剂治疗试验已经启动。我们研究的目的是评估联合治疗前后滑膜肉瘤中HER2、EGFR和TOPIIA的状态。进行了免疫组化和FISH检测。发现蛋白表达与基因状态之间存在显著差异。作者讨论了该现象的潜在原因。
